Home > Boards > US Listed > Biotechs > Aduro Biotech (KDNY)

Better alternatives than paying 150% one day later

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
rtraster Member Profile
 
Followed By 6
Posts 245
Boards Moderated 0
Alias Born 09/05/13
160x600 placeholder
Chinook Therapeutics to Present at the William Blair Biotech Focus Conference 2021 GlobeNewswire Inc. - 7/12/2021 4:05:00 PM
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. - 7/7/2021 4:05:00 PM
Geron, AnPac Bio-Medical Science leads healthcare gainers; Orphazyme, Athira Pharma among major losers Seeking Alpha - 6/18/2021 11:01:18 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/18/2021 6:06:18 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2021 6:40:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2021 5:26:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/9/2021 6:15:02 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/9/2021 4:23:43 PM
Chinook Therapeutics names new COO and CSO Seeking Alpha - 6/9/2021 8:24:53 AM
Chinook Therapeutics Announces Promotions of Tom Frohlich to Chief Operating Officer and Andrew King, D.V.M, Ph.D., to Chief ... GlobeNewswire Inc. - 6/9/2021 8:15:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/8/2021 6:08:10 PM
Chinook Therapeutics Presents BION-1301 Interim Phase 1/2 Data in Patients with IgA Nephropathy (IgAN) at the 58th ERA-EDTA V... GlobeNewswire Inc. - 6/8/2021 8:15:00 AM
Chinook Therapeutics to Host Conference Call and Webcast Featuring BION-1301 Data Presented at the 58th ERA-EDTA Congress GlobeNewswire Inc. - 5/25/2021 4:05:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/18/2021 5:02:13 PM
Chinook Therapeutics to Present at the 2021 RBC Capital Markets Global Healthcare Conference GlobeNewswire Inc. - 5/13/2021 4:05:00 PM
Chinook Therapeutics EPS misses by $0.24, beats on revenue Seeking Alpha - 5/12/2021 4:46:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/12/2021 4:10:58 PM
Chinook Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results GlobeNewswire Inc. - 5/12/2021 4:05:00 PM
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. - 5/4/2021 4:15:00 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/23/2021 4:11:59 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/23/2021 4:08:39 PM
Chinook Therapeutics Presents Data During the ISN World Congress of Nephrology 2021 GlobeNewswire Inc. - 4/15/2021 8:15:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 4/15/2021 7:41:06 AM
Chinook Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire Inc. - 4/8/2021 4:30:00 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 4/7/2021 5:29:13 PM
rtraster   Thursday, 04/16/15 10:19:35 AM
Re: None
Post # of 106 
Better alternatives than paying 150% one day later
So at this point, you can either agree that this company is worth 150% more than it was yesterday, even though it hasn't changed whatsoever as a company, or you could look for alternatives.

Hint: Paying an extra 150% the day after an IPO is a losing strategy since 1999, learn your history lesson.

Wait. I'm following Dr. Frost into a similar company in the same space, MBVX, but even if you want to stick with Aduro then you should look into the relationship it has with other companies and Adam Feuerstein's recent commentary which is very enlightening re: another public company in this space.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences